NCT02158091 2026-02-13
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT03534323 2025-08-14
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT06810778 2025-07-15
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT02391545 2023-09-28
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
SecuraBio
Phase 1/2 Terminated